Linkedin iconTwitter iconFacebook iconGoogle+ iconRSS icon 

Young Investigator's Symposium

The Division is now accepting nominations for speakers at the Young Investigator's Symposium to be held at the Fall 2015 ACS meeting. Appropriate candidates will be independent investigators who are no more than 10 years from graduate school or post-doctoral appointment, be a current researcher in a non-academic setting (e.g. industry, government or non-profit laboratory) and have demonstrated outstanding promise for future contributions to Organic Chemistry. A nomination letter should be written by the head of a department or division, and should highlight the scientist's promise, creativity, and productivity. Importantly, please also address the nominee's ability to present a 30 minute scientific talk at the Fall 2015 ACS meeting that contains a substantial amount of the scientist's own work, along with a very brief description of the talk's topic. A copy of the candidate's CV should also be included. We understand that certain settings may not encourage frequent publications, and accordingly, publication record will not be a primary criterion for an invitation to speak. As our goal is to put together a symposium of young, up-and-coming scientists from a range of backgrounds, organizations and industries, please suggest only one individual from your organizations. Nominations should be submitted electronically as a pdf file to Spencer Dreher (spencer_dreher@merck.com) by February 3, 2015. We expect to make invitations to speakers shortly thereafter.

Thanks for your support of this program, and for your willingness to help develop young scientists by providing them with opportunities to speak at a national meeting and to interact with other scientists. If you have any questions, please do not hesitate to contact Dr. Dreher.


2015 Young Investigator's Symposium

Gregg Keaney, H3 Biomedicine
Total synthesis of 6-deoxypladienolide D and assessment of splicing inhibitory activity in a mutant SF3B1 cancer cell line

Roy Helmy, Merck
Development and implementation of innovative high-throughput screening and analysis solutions to support discovery and development of active pharmaceutical ingredients in the pharmaceutical industry

Patricia Brieva, L'Oreal
Organic acid applications within the cosmeceutical industry “chemical peels”

Reema Thalji, GlaxoSmithKline
Structure-guided design and optimization of fluoroquinolone-substituted bacterial type IIA DNA topoisomerase inhibitors

Paul LaBeaume, Dow Chemical
Application of synthetic organic chemistry in the design of cationic initiators for next generation photoresists

Kevin Cole, Eli Lilly
Continuous processing: Chemical route development and GMP implementation

Timothy Briggs, Ensemble Therapeutics
DNA-programmed chemistry toward macrocycle libraries for drug discovery

Andrew Vetter, Eastman Chemical
Cobalt catalyzed reductive carbonylation of methanol

Andrew Hejl, Dow Chemical
Designed hybridization – acrylic-epoxy hybrid dispersions for industrial coating applications

Nathan Ide, Pfizer
Development of a commercial manufacturing process for Ibrance® (palbociclib)

Jeffrey Kallemeyn, AbbVie
Approaches to the heterocyclic core of Ilorasertib

Andrew Satterfield, DuPont
Carbonyl containing heterocycles as aromatic isosteres in 4-hydroxyphenylpyruvate dioxygenase (HPPD) herbicides

Antonella Converso, Merck
Discovery of adenosine analog inhibitors of S-adenosylhomocysteine hydrolase

Ke Chen, Bristol-Myers-Squibb
Overcoming steric and electronic obstacles: Development of efficient syntheses of active pharmaceutical ingredients

Martin Schnermann, National Cancer Institute
Near-IR uncaging chemistry: Discovery and applications

Sheng Cui, Amgen
Chiral chemistry for API synthesis

2014 Young Investigator's Symposium

Nicole Knight, Dow Chemical
Multidisciplinary problem solving in industrial research

Anthony A Estrada, Genentech
Access to potent, selective, efficacious, and highly functionalized pyrimidoaminotropane mTOR inhibitors through the development of a flexible pyrimidine methodology

Christoph W Zapf, Pfizer
Lessons learned from targeting interleukin-2 inducible T cell kinase (ITK) by a covalent approach

Kelly M George, L'Oreal
Development of new skin care cleansing formulations using design of experiment and fast formulation tools

Beth M. Cooper, Dow Chemical
Latex-pigment interactions in paint to reduce environmental impact and improve performance

Rebecca T Ruck, Merck
MK-7655: Surprising synthetic complexity for seemingly straightforward steps

Adrian Ortiz, Bristol-Myers-Squibb
Discovery of an innovative stereoselective synthesis of BMS-986001: A nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection

Sébastien Lemaire, Janssen Pharmaceutica
Stereoselective C-glycosylation reactions with arylzinc reagents

Shashank Shekhar, AbbVie
Discovery of novel catalytic technologies in the process development of HCV polymerase inhibitors

Jared L Piper, Eli Lilly
Process development and synthetic approaches for a CB1 inverse agonist

2013 Young Investigator's Symposium

Santhosh F Neelamkavil, Merck
Discovery of bridged bicyclic piperidines as GPR119 agonists for the treatment of Type 2 diabetes

Kurt Hirsekorn, Dow Chemical
Selective methane activation and chlorocarbon development for climate friendly refrigerants via free radical chemistries

John S. Schneekloth, National Cancer Institute
Chemical probes of protein sumoylation: Strategies and tactics

David L Gray, Pfizer
Medicinal chemistry at the blood-brain interface: Challenge and opportunity

Shawn D. Walker, Amgen
Development of new methods for the asymmetric synthesis of small molecule drug candidates

Allyn T Londregan, Pfizer
Synthetic enablement for drug discovery: A new method for the addition of nucleophiles to pyridine-N-oxides

Owendi Ongayi, Dow Electronic Materials
Development of materials for semiconductor device fabrication

Rami Hannoush, Genentech
Peptides tools for targeting the zymogen form of a caspase

Artis Klapars, Merck
Asymmetric synthesis of complex drug targets

2012 Young Investigator's Symposium

Michael T Rudd, Merck
Discovery of vaniprevir (MK-7009) and MK-5172: Macrocyclic HCV NS3/4a protease inhibitors

Stephen M. Lynch, Hoffmann-La Roche
Design and synthesis of novel monoamine triple reuptake inhibitors

Jason S Tedrow, Amgen
Route selection toward AMG 222: A direct tetrazole addition strategy toward building molecular complexity

Ming Xu, DuPont Crop Protection
Synthesis and crop protection utility of novel fused heterobicyclic isoxazolines

Ed Cleator, Merck
Discovery of an asymmetric synthesis of suvorexant

Lori Krim Gavrin, Pfizer
Adventures in medicinal chemistry: Drug design and probe design

Xing Dai, Merck
Example of drug discovery program leading to the development of novel reactions

2011 Young Nonacademic Investigators

Vincent Mascitti, Pfizer
Discovery of clinical candidate PF-04971729: An anti-diabetic agent from the structurally unique dioxa-bicyclo[3.2.1]octane class of SGLT2 inhibitors

Lisa A Marcaurelle, Broad Institute
Diversity-oriented synthesis: From macrocyclesto spirocycles and beyond

Brian C Shook, Johnson & Johnson
Indenopyrimidines as dual adenosine A2A/A1 antagonists for the treatment of Parkinson's disease

Aaron T Wright, Pacific Northwest National Laboratory
Identification of proteins relevant to bioenergy and disease pathology by chemical proteome profiling

Spencer D Dreher, Merck
Collaboration and communication in chemistry

Ted W Johnson, Pfizer
HIV integrase and the Golden Triangle: Overcoming synthetic challenges to compounds occupying unique chemical space

2010 Young Nonacademic Investigators

Vassil I Elitzin, GlaxoSmithKline
Efficient and practical synthesis of GSK812397, an HIV drug candidate

Qinhua Huang, Pfizer
Synthesis and evaluation of NO donor containing carbonic anhydrase inhibitors

Andrew W Fraley, Ensemble Discovery
DNA-programmed chemistry approaches to macrocyclic lead compounds

Catherine A Faler, ExxonMobil Chemical Company
Synthesis of pyridyl amine ligands for catalyzed ethylene oligomerization

Robert D Mazzola Jr., Merck/Ligand Pharmaceuticals
Design and synthesis of novel β-secretase (BACE) inhibitors

Hannah Yu, Eli Lilly
Development of an efficient palladium-catalyzed intramolecular carbometalation reaction for the synthesis of a dibenzoxapine-containing tetrasubstituted exocyclic alkene

Fa Liu, National Cancer Institute
Peptide mimetics disrupting protein-protein interactions discovered by post-solid phase modifications

Francis Gosselin, Merck
Asymmetric hydrogenation of unprotected N-H ketoimines

Nidhi Gupta, Biodesign Institute, Arizona State University
Synthetic ligands (synbodies): Syntheticalternatives to antibodies

Matthew M Bio, Amgen
Practial arene metallation chemistry

2009 Young Investigator's Symposium

Craig J. Thomas, National Institutes of Health
Bioactive small molecule discovery at the NIH chemical genomics center

David Tellers, Merck
Application of automation to synthetic organic challenges Shawn M. Dirk, Sandia National Laboratories
Development of novel polymeric capacitor dielectric materials

Xianhai Huang, Schering-Plough Research Institute
Total synthesis and SAR development of potent antitumor natural product psymberin/irciniastatin A

Andrew E. Taggi, DuPont Crop Protection
Chemistry at the interface of agriculture and medicine: Pyrazinones as tubulin modulators

Dafydd R. Owen, Pfizer
Enabling the hit to lead process at Pfizer: The value of organic synthesis

M. Uljana Mayer, Pacific Northwest National Laboratory
New probes for proteomics: Synthesis and application to problems in health and bioenergy

Karin M. Balss, Cordis Corporation
Investigation of chemical spatial distribution of drug and polymer in drug-eluting stent coatings

Stefan G. Koenig, Sepracor
Lessons learned: Development of a catalytic asymmetric hydrogenation process

Daniel H. Appella, National Institutes of Health
Molecular designs for peptide nucleic acids in detection and multivalent platforms

Eric Assen B. Kantchev, Forma Therapeutics Singapore
Rational exploration and exploitation of palladacycle diversity: Design and development of the SingaCycle family of NHC-palladacycle cross-coupling catalysts

Oliver Thiel, Amgen
Synthesis and process development of an advanced drug candidate

Jeffrey C. Gildersleeve, National Cancer Institute
Multidimensional carbohydrate microarrays for cancer research

2008 Young Investigator's Symposium

Yue-Mei Zhang, Johnson & Johnson
Regioselective Pd-catalyzed coupling of halopyrimidines and synthesis of functionalized pyrimidoindole heterocycles

Shane W. Krska, Merck
Harnessing the power of high-throughput experimentation for catalytic reaction development at Merck

Percy H. Carter, Bristol-Myers Squibb
Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2

Florence Mehlmann, Arkema
Developments of new polymer architectures by controlled radical polymerization

Zhao-Kui Wan, Wyeth Research
Serendipitous synthetic discoveries: A tale of phosphonium and oxybenzotriazole chemistry

Daniel Steiger, General Electric Global Research
Rational design of surfaces with nanometer-sized domains for improved blood compatibility

Kanth V. B. Josyula, Aldrich Chemical Company
Enabling boron-based reagents in chemical synthesis: A story of advancing science through new product development at Aldrich

Brian A. Johns, GlaxoSmithKline
Novel synthetic methods to facilitate the pursuit of antiviral drugs

Erik J Hembre, Eli Lilly
Discovery of the NK-1 antagonist LY686017

2007 Young Investigator's Symposium

J. Kent Barbay, Johnson & Johnson
Synthesis and evaluation of small molecule C5a receptor antagonists

Kevin R Campos, Merck
Enantioselective arylation of N-Boc pyrrolidine

Robert M. Borzilleri, Bristol-Myers Squibb
From cytotoxic agents to targeted therapies: A new era in oncology research

Robert A. Singer, Pfizer
Development of nonproprietary catalysts for the palladium-catalyzed amination reaction

Edmund I. Graziani, Wyeth Research
Synthesis and chemical biology of ILS-920: A novel non-immunosuppressive rapamycin analog with efficacy in multiple animal models of ischemic stroke